Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving in adults with alcohol use disorder (AUD), a phase II randomized trial showed.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.

Since weight-loss drugs that target the hormone GLP-1 have surged in popularity, some additional health benefits have emerged. Beyond helping people shed pounds, they also lower the risk of heart disease and sleep apnea—and the U.